Cathie Wood’s ARK buys Tempus AI stock, sheds Rocket Lab

Published 13/03/2025, 01:06
Cathie Wood’s ARK buys Tempus AI stock, sheds Rocket Lab

Cathie Wood’s ARK ETFs have reported their daily trades for Wednesday, March 12th, 2025, with a notable focus on the healthcare and technology sectors. Leading the day’s transactions was a substantial purchase of TEMPUS AI INC (NASDAQ:TEM) shares, with ARK’s flagship innovation fund ARKK acquiring 29845 shares valued at approximately $1,360,335. This move underscores ARK’s continued confidence in the artificial intelligence-driven biotech company, following a pattern of accumulation in recent days.

In the realm of aerospace and defense, ARK’s funds ARKQ and ARKX (NYSE:ARKX) bought a combined total of 7940 shares of AEROVIRONMENT INC (NASDAQ:AVAV), with a total dollar value of $984,560. This purchase comes after a smaller acquisition of the company’s shares just the day before, signaling a growing interest in the unmanned aircraft systems manufacturer.

ARK also increased its stake in the gene-editing space with the purchase of 10671 shares of CRISPR THERAPEUTICS AG (NASDAQ:CRSP) for $452,130 and 18120 shares of INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) for $168,516, spread across its ARKK and ARKG ETFs. These transactions reflect ARK’s ongoing investment in disruptive genomic technologies.

On the sell side, ARK divested a significant number of shares from several companies. The most substantial sale was 41839 shares of ROCKET LAB USA INC (NASDAQ:RKLB), split between ARKQ and ARKX ETFs, with a total dollar value of $745,989. This move suggests a scaling back of ARK’s position in the space launch service provider, a contrast to the buying trend observed with AEROVIRONMENT INC.

Other notable sales included 140707 shares of PRIME MEDICINE INC (NASDAQ:PRME) from ARKK, totaling $267,343, and 9961 shares of CAREDX INC (NASDAQ:CDNA) from ARKG, amounting to $183,282. Additionally, 39431 shares of REPARE THERAPEUTICS INC (NASDAQ:RPTX) were sold through the ARKG ETF for $45,345.

Smaller transactions included the purchase of 1193 shares of IBOTTA INC (NYSE:IBTA) across ARKW and ARKF ETFs, valued at $46,622. This follows a more significant investment in the company earlier in the week, indicating ARK’s sustained interest in the mobile technology firm.

Investors following ARK’s trading activity may find these trends and changes in positions indicative of the fund’s strategic direction, with a clear focus on innovative companies poised for growth in their respective industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.